Bioniche Life Sciences, Inc. - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Bioniche Life Sciences, Inc. - Product Pipeline Review - 2014" provides data on the Bioniche Life Sciences, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Bioniche Life Sciences, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Bioniche Life Sciences, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Bioniche Life Sciences, Inc. - Brief Bioniche Life Sciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bioniche Life Sciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bioniche Life Sciences, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bioniche Life Sciences, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Bioniche Life Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bioniche Life Sciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bioniche Life Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bioniche Life Sciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bioniche Life Sciences, Inc. and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Bioniche Life Sciences, Inc. Snapshot 4
Bioniche Life Sciences, Inc. Overview 4
Key Information 4
Key Facts 4
Bioniche Life Sciences, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Bioniche Life Sciences, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Bioniche Life Sciences, Inc. - Pipeline Products Glance 9
Bioniche Life Sciences, Inc. - Late Stage Pipeline Products 9
Phase III Products/Combination Treatment Modalities 9
Bioniche Life Sciences, Inc. - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Bioniche Life Sciences, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Bioniche Life Sciences, Inc. - Drug Profiles 12
EN-3348 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Mycobacterial Cell Wall-DNA Complex Program 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Oligonucleotides 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Bioniche Life Sciences, Inc. - Pipeline Analysis 16
Bioniche Life Sciences, Inc. - Pipeline Products by Therapeutic Class 16
Bioniche Life Sciences, Inc. - Pipeline Products by Route of Administration 17
Bioniche Life Sciences, Inc. - Pipeline Products by Molecule Type 18
Bioniche Life Sciences, Inc. - Recent Pipeline Updates 19
Bioniche Life Sciences, Inc. - Dormant Projects 21
Bioniche Life Sciences, Inc. - Discontinued Pipeline Products 22
Discontinued Pipeline Product Profiles 22
EN-3348 22
Bioniche Life Sciences, Inc. - Company Statement 23
Bioniche Life Sciences, Inc. - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Bioniche Life Sciences, Inc. - Key Manufacturing Facilities 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables
Bioniche Life Sciences, Inc., Key Information 4
Bioniche Life Sciences, Inc., Key Facts 4
Bioniche Life Sciences, Inc. - Pipeline by Indication, 2014 6
Bioniche Life Sciences, Inc. - Pipeline by Stage of Development, 2014 7
Bioniche Life Sciences, Inc. - Monotherapy Products in Pipeline, 2014 8
Bioniche Life Sciences, Inc. - Phase III, 2014 9
Bioniche Life Sciences, Inc. - Phase I, 2014 10
Bioniche Life Sciences, Inc. - Preclinical, 2014 11
Bioniche Life Sciences, Inc. - Pipeline by Therapeutic Class, 2014 16
Bioniche Life Sciences, Inc. - Pipeline by Route of Administration, 2014 17
Bioniche Life Sciences, Inc. - Pipeline by Molecule Type, 2014 18
Bioniche Life Sciences, Inc. - Recent Pipeline Updates, 2014 19
Bioniche Life Sciences, Inc. - Dormant Developmental Projects,2014 21
Bioniche Life Sciences, Inc. - Discontinued Pipeline Products, 2014 22
Bioniche Life Sciences, Inc., Other Locations 25
Bioniche Life Sciences, Inc., Subsidiaries 26
Bioniche Life Sciences, Inc., Key Manufacturing Facilities 27